Drug

Novartis' Rhapsido (Remibrutinib) Wins FDA Approval – First‑in‑Class BTK Inhibitor Becomes First Approved Treatment for Symptomatic Dermographism
NovartisNYSE: NVS

Novartis’ Rhapsido (Remibrutinib) Wins FDA Approval – First‑in‑Class BTK Inhibitor Becomes First Approved Treatment for Symptomatic Dermographism

Novartis AG (NYSE: NVS) announced that the U.S. Food and Drug Administration (FDA) has approved Rhapsido® (remibrutinib), an oral, highly selective Bruton's tyrosine kinase inhibitor (BTKi), for the treatment of…

Pfizer's TUKYSA Wins FDA Approval for First‑Line Maintenance in HER2+ Metastatic Breast Cancer – Chemotherapy‑Free Tucatinib Combination Delivers 36% Reduction in Progression Risk

Pfizer’s TUKYSA Wins FDA Approval for First‑Line Maintenance in HER2+ Metastatic Breast Cancer – Chemotherapy‑Free Tucatinib Combination Delivers 36% Reduction in Progression Risk

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World's First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World’s First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Clinical trial approval / initiationRNAi / ASO

Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval

Hengrui's HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure
ADC / XDCClinical trial results

Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure

ADC / XDCClinical trial results

Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial

GSK's Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk
GlaxoSmithKlineGSK

GSK’s Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk

Show More